Reveleer vs Xsolis (2026)
Two platforms bought by the same risk bearing organization for different parts of the year. Reveleer works retrospectively, retrieving records, parsing charts and populating risk adjustment and quality submissions, which is how a contract year gets closed once the visits are gone. Xsolis works in the moment, scoring medical necessity continuously between payer and provider so both sides argue from the same number, with peer reviewed research behind that score and a stated HITRUST certification. They are not alternatives. What they share is an unanswered question apiece: Reveleer should be asked its ratio of codes removed to codes added, and Xsolis the proportion of AI informed adverse determinations overturned on appeal. Those two numbers describe whether either system is calibrated or merely productive.
- It works after the encounter, retrieving records, parsing charts and populating both risk adjustment and quality submissions, which is the machinery that closes a contract year.
- Retrieval is the hard part of retrospective work and it owns that step rather than assuming charts arrive.
- Quality reporting sits alongside risk adjustment in one platform, so a single workflow serves two regulatory obligations.
- It sits between payer and provider rather than serving one side, scoring medical necessity continuously so both parties argue from the same number.
- Peer reviewed research on its score is published from studies across several United States health systems.
- It states HITRUST risk based certification at the two year tier.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Reveleer and Xsolis are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Reveleer | Xsolis |
|---|---|---|
| Primary category | Value Based Care Intelligence | RCM & Prior Auth AI |
| Founded | 2009 | 2013 |
| Headquarters | Glendale, California, United States | Franklin, Tennessee |
| Website | reveleer.com | xsolis.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
Xsolis
-
Product / capability
Xsolis launched GenAI Peer-to-Peer Clinical Synopsis as an add on inside Dragonfly Advise.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
Reveleer is a Glendale, California company founded in 2009 as a medical record retrieval business and since rebuilt as a value based care platform for health plans and risk bearing providers across Medicare Advantage, ACA Marketplace and Medicaid.
Source: AI Health Index, September 2026
Xsolis sells AI utilization management to hospitals and health plans. Its Dragonfly platform scores each admitted patient's likelihood of needing inpatient care or observation, using machine learning over the hospital record, so the hospital and the payer can work from the same clinical evidence when they decide status and concurrent authorization.
Source: AI Health Index, September 2026
Questions buyers ask
How do Reveleer and Xsolis work with the EHR?
For Reveleer, the EVE page says prospective insights are delivered directly into point of care record workflows, and the company's clinical data repository page says it integrates with record systems, health information exchanges, retrieval vendors and internal data warehouses, with charts moved by bulk upload, SFTP or API.
With Xsolis, the shared clinical access between a health system and its payers through Dragonfly is a distinct integration pattern, since both parties read the same record view. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
How are Reveleer and Xsolis priced and sold?
In Reveleer's case, one possibility is specific to risk adjustment, where a vendor is sometimes paid a share of the incremental payment its work produces. If any part of an arrangement is contingent on conditions found, the fee runs the same direction as the coding, and the party absorbing an over captured condition is the federal program rather than the plan.
For Xsolis, the offering is a hybrid: alongside the platform the company sells Physician Advisor Services covering night and weekend gaps or operating fully outsourced, so the buy can be software, staffed service, or both. A clinical staffing component behaves very differently from a license. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
How do Reveleer and Xsolis handle patient data?
With Reveleer, the company has described processing over 1.2 billion pages of clinical data a year for more than 55 health plans.
Xsolis announced HITRUST r2 certification for the platform in March 2022 and described it as a proactive approach to protecting health information; the website privacy policy covers site visitors only. Nothing published states how long clinical data drawn from hospital records is kept, whether it is de identified, or whether it trains the Care Level Score. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
What evidence is published for Reveleer and Xsolis?
For Reveleer, the EVE page reports a 3X noise reduction, described in the same sentence as cutting false positives and irrelevant suspects in half compared with legacy NLP, and a 33 percent improvement in RAF accuracy that it says EVE's confidence score has helped health plans achieve; a case study on clinical coding precision is linked.
With Xsolis, the Care Level Score predicted inpatient discharge status with an area under the curve of 0.89, and a score of 76 or higher classified status correctly 86 percent of the time. Combining the score with a commercial screening tool did worse than the score alone. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 22, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers.
These serve adjacent functions inside a risk bearing organization and neither publishes the number its own category most needs. For retrospective risk adjustment that is the ratio of codes removed to codes added, since a platform tuned to find more and one tuned to find correctly look identical on every reported metric. For utilization management it is the proportion of AI informed adverse determinations overturned on appeal.
Neither publishes bias findings or subgroup analysis; Reveleer describes bias and drift checks inside its governance framework without publishing results, and in utilization management an output can end in care being denied.